Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ifosfamide
Drug ID BADD_D01133
Description Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
Indications and Usage Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.
Marketing Status approved
ATC Code L01AA06
DrugBank ID DB01181
KEGG ID D00343
MeSH ID D007069
PubChem ID 3690
TTD Drug ID D02TLO
NDC Product Code 10019-925; 57884-0006; 63323-142; 0143-9531; 0338-3991; 15308-0411; 0338-3993; 65124-0001; 0143-9530; 10019-926; 10019-927; 10019-929
UNII UM20QQM95Y
Synonyms Ifosfamide | Isofosfamide | Isophosphamide | Iphosphamide | Iso-Endoxan | Iso Endoxan | Holoxan | NSC-109,724 | NSC 109,724 | NSC109,724 | NSC-109724 | NSC 109724 | NSC109724 | Asta Z 4942
Chemical Information
Molecular Formula C7H15Cl2N2O2P
CAS Registry Number 3778-73-2
SMILES C1CN(P(=O)(OC1)NCCCl)CCCl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Malignant neoplasm progression16.16.01.0050.000280%-
Acute coronary syndrome02.02.02.015; 24.04.04.011---
Necrotising colitis07.08.01.013---
Lymphatic disorder01.09.01.003---
Fanconi syndrome acquired14.01.01.013; 20.05.03.0120.000112%-
Drug tolerance decreased08.06.01.0240.000112%-
Protein urine present13.13.02.006---
Musculoskeletal discomfort15.03.04.001---
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.0010.000168%-
Febrile bone marrow aplasia01.03.03.007; 08.05.02.0050.000112%-
Growth retardation05.03.02.007; 14.03.02.031; 15.03.05.0160.000112%
Infusion site reaction08.02.05.005; 12.07.05.006---
Urine phosphorus increased13.11.01.047---
Electrocardiogram U-wave abnormality13.14.05.028---
Brain cancer metastatic16.30.04.001; 17.20.04.001---
Haemorrhage24.07.01.002---
Major depression19.15.01.003---
Angiopathy24.03.02.007---
Metastases to central nervous system16.22.02.004; 17.02.10.013---
Epidermal necrosis23.03.03.035---
Urine output increased13.13.03.002---
Recall phenomenon12.02.06.001; 23.03.07.005--
Adverse event08.06.01.0100.000168%-
Breast disorder21.05.04.004---
Cardiac disorder02.11.01.003---
Connective tissue disorder10.04.04.026; 15.06.01.006---
Haematotoxicity01.05.01.007; 12.03.01.0250.000280%-
Infestation11.09.01.001; 23.11.01.002---
Inflammation08.01.05.007; 10.02.01.089---
Malnutrition14.03.02.004---
The 11th Page    First    Pre   11 12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene